This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Fenfluramine in Dravet syndrome

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Dravet Syndrome (DS) is a rare epileptiform disorder typically presenting within the first year of life of a normally developing infant

  • is characterized by several prolonged seizures that are often resistant to current anti-epileptic drug (AED) regimens

Fenfluramine (3-trifulormethyl-N-ethylamphetamine)

  • is an amphetamine derivative that primarily affects serotonin neurotransmitter levels
  • was initially prescribed in the 1960s as an appetite suppressant marketed as a weight loss drug
  • is an amphetamine derivative that was found to have anti-epileptic effects since 1980s (2)
    • mechanism by which Fenfluramine treats seizures is believed to be through regulation of serotonin signaling
    • invertebrate animal models with SCN1A mutations demonstrate activity at 5-HT1D and 5-HT2C receptors
  • was removed from the markets due to its association with cardiac valvopathies (1)
    • medication became popular in the 1990s as an appetite suppressant but was removed from the market due to cardiovascular complications at high doses (2)
  • with respect to use in Dravet syndrome (1):
    • success of the randomized control trials suggests the addition of fenfluramine to current AED regimens may lead to better control of seizures in patients with Dravet syndrome
    • side effects of fenfluramine prove to be manageable and the concern for valvopathies has not been reproducible with low dose fenfluramine
    • weight loss was a mild side effect that should be well-tolerated if a patient experiences seizure reduction (2)

NICE state:

  • Fenfluramine is recommended as an add-on to other antiseizure medicines for treating seizures associated with Dravet syndrome in people aged 2 years and older, only if:
    • seizures have not been controlled after trying 2 or more antiseizure medicines
    • the frequency of convulsive seizures is checked every 6 months, and fenfluramine is stopped if it has not fallen by at least 30% compared with the 6 months before starting treatment
    • the company provides fenfluramine according to the commercial arrangement
  • the NICE committee state:
    • "..Treatment for Dravet syndrome often starts with a single antiseizure drug such as sodium valproate. Other treatments can then be added if seizures are not well controlled. In practice, standard care often involves a combination of 3 antiseizure medicines. Clinicians may offer add-on therapies such as cannabidiol with clobazam, or fenfluramine.."

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.